Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study

医学 阿达木单抗 溃疡性结肠炎 内科学 安全概况 重症监护医学 不利影响 疾病
作者
Nicholas Michael Croft,William A. Faubion,Subra Kugathasan,Jarosław Kierkuś,Frank M. Ruemmele,Toshiaki Shimizu,Nael Mohamed Mostafa,Mary Venetucci,Tricia K. Finney‐Hayward,Yuri Sánchez González,Mareike Bereswill,Andreas Lazar,Dan Turner
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:6 (8): 616-627 被引量:90
标识
DOI:10.1016/s2468-1253(21)00142-4
摘要

Background Biologic treatment options are limited for children with ulcerative colitis. The aim of this study was to assess the safety and efficacy of adalimumab in children with moderate-to-severe ulcerative colitis. Methods The double-blind ENVISION I study was done at 24 hospitals in ten countries. Children (4–17 years) with moderate-to-severe ulcerative colitis despite stable doses of concurrent treatment with oral corticosteroids or immunosuppressants were enrolled. Per the original study design, patients were randomly assigned with an Interactive Voice Response System (IVRS) to receive either high-dose induction adalimumab (2·4 mg/kg [maximum 160 mg] at weeks 0 and 1) or standard-dose induction adalimumab (2·4 mg/kg at week 0 and placebo at week 1); both groups received 1·2 mg/kg (maximum 80 mg) at week 2 and 0·6 mg/kg (maximum 40 mg) at weeks 4 and 6. Patients with partial Mayo score (PMS) response at week 8 (defined as a decrease of two or more points and a decrease of ≥30% from baseline in PMS) were randomly assigned (2:2:1)—using IVRS—to receive either high-dose maintenance adalimumab (0·6 mg/kg weekly), standard-dose maintenance adalimumab (0·6 mg/kg every other week), or placebo up to week 52 (random assignment to the placebo group was ceased mid-trial, as was randomisation in the induction phase with all subsequent patients receiving open-label high-dose induction adalimumab). Coprimary endpoints were the proportion of patients with PMS remission at week 8 (intent-to-treat [ITT]-E population, not including those patients who were not randomised in the induction phase) and full Mayo score (FMS) remission at week 52 in week 8 PMS responders (maintenance ITT-E [mITT-E] population), for which the pooled adalimumab group (patients who received high-dose or standard-dose adalimumab) and the individual dose groups were compared against external adult placebo rates. We report results of the final confirmatory analysis. This trial is registered with ClinicalTrials.gov, NCT02065557. Findings 93 children were recruited between Oct 13, 2014, and Sept 5, 2018, to the main study (77 [83%] were randomly assigned [double-blind] to receive high-dose or standard-dose induction adalimumab; 16 [17%] received open-label high-dose induction adalimumab after study design change). At week 8, 74 (80%) children who were PMS responders continued to the maintenance period. 62 (84%) patients were randomly assigned to receive high-dose or standard-dose maintenance adalimumab treatment; 12 (16%) patients received placebo. In patients in the ITT-E population who were randomly assigned to receive high-dose induction adalimumab, a significantly higher proportion of patients were in PMS remission at week 8 (28 [60%] of 47) compared with external placebo (19·8%; p=0·0001). 13 (43%) of 30 patients in the standard-dose induction adalimumab group were in PMS remission at week 8 versus an external placebo rate of 19·8%, but this difference was not significant (p=0·38). Similarly, FMS remission at week 52 in children who were week 8 PMS responders was reported in a significantly higher proportion of patients in mITT-E population who received high-dose maintenance adalimumab (14 [45%] of 31 patients) versus external placebo at week 52 (18·4%; p=0·0001). Nine (29%) of 31 patients in the standard-dose maintenance adalimumab group were in FMS remission at week 52 versus an external placebo rate of 18·4%, but this difference was not significant (p=0·38). Remission rates in the pooled adalimumab groups were significantly better compared with external placebo (PMS remission at week 8: 41 [53%] of 77 patients; p<0·0001; FMS remission at week 52: 23 [37%] of 62 patients; p=0·0001). 21 (23%) of 93 patients in the main study had one or more treatment-emergent serious adverse events during any adalimumab exposure. The most common adverse events were headache, anaemia, and ulcerative colitis flare during the induction period and ulcerative colitis flare, headache, and nasopharyngitis during the maintenance period. Interpretation Clinically meaningful rates of remission and response were reported in children who received adalimumab in this study. No new safety signals were observed, suggesting that adalimumab is an efficacious and safe treatment option for children with moderate-to-severe ulcerative colitis. Funding AbbVie.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dio发布了新的文献求助10
1秒前
a雪橙发布了新的文献求助10
1秒前
liutao发布了新的文献求助200
1秒前
冲冲冲发布了新的文献求助10
2秒前
makg发布了新的文献求助10
2秒前
秋天的雪完成签到,获得积分10
3秒前
3秒前
科研通AI6.3的应助被jyxm采纳,获得10
3秒前
隐形曼青的应助被neighborhood采纳,获得10
3秒前
fantasy的应助被大拉花采纳,获得10
3秒前
呼呼呼呼发布了新的文献求助10
3秒前
酷波er的应助被skyla~采纳,获得10
5秒前
仇道罡发布了新的文献求助10
5秒前
5秒前
小汤完成签到 ,获得积分10
5秒前
陈磨磨磨发布了新的文献求助10
5秒前
李健的粉丝团团长的应助被WYL采纳,获得10
5秒前
秋天完成签到 ,获得积分10
6秒前
6秒前
聂的苏发布了新的文献求助30
6秒前
好好活着完成签到,获得积分10
7秒前
上官若男的应助被大气摩托采纳,获得10
7秒前
烟花的应助被恒驰采纳,获得10
7秒前
dio完成签到,获得积分10
7秒前
8秒前
8秒前
8秒前
Jyouang发布了新的文献求助10
9秒前
9秒前
9秒前
wjwnb666完成签到,获得积分10
10秒前
10秒前
10秒前
暴躁莹子发布了新的文献求助20
11秒前
12秒前
QIAN完成签到,获得积分10
12秒前
12秒前
0529完成签到,获得积分10
13秒前
无极微光的应助被恒驰采纳,获得20
13秒前
怡迦完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417